While the United States and Europe medical device segments face backlash from the economic slowdown, the Russia-Ukraine war, and the cost-of-living crisis, the APAC (Asia-Pacific) medical devices landscape continues to record phenomenal growth. However, 2023 will be challenging for APAC medtech due to uncertainties arising from the anticipated market slowdown and other macroeconomic factors. Bank failures in the United States also continue to create ripple effects in APAC, with Credit Suisse being the latest. In this growth opportunity analysis, Frost & Sullivan analyzes the APAC medical devices space, including macroeconomic factors and the latest developments. Major medical device segments covered include orthopedics, cardiology, respiratory, diabetes, wound care, and others.
• How will the digitalization of medical devices impact original equipment manufacturers’ operations?
• Which factors will lead medtech participants to explore new business models and disruptive technologies?
• How will the transition of conventional approaches to healthcare innovation involves an extensive coalition of healthcare stakeholders?
• What are the new methods that combine diagnostics, devices, digital tools, emerging technologies, and medication to deliver improved patient outcomes?
• Which innovative opportunities will arise from the increased inclusiveness of underserved patient populations, robotics adoption, and the transition of care from hospitals to home-based models?
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured open discussion with our growth experts providing unparalleled industry intelligence, technology advancements, and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
